培美曲塞联合奈达铂治疗晚期乳腺癌的近期疗效  

Short-term efficacy of combination chemotherapy with pemetrexed and nedaplatin in the treatment of advanced breast cancer

作　　者：郑向欣[1] 管小青[1] 吴骥[1] 顾书成 袁牧[1] 张旭旭[1] 

机构地区：[1]南京鼓楼医院集团宿迁市人民医院甲乳外科,江苏宿迁223800

出　　处：《中国肿瘤外科杂志》2014年第1期12-15,共4页Chinese Journal of Surgical Oncology

基　　金：江苏省卫生厅资助项目(H200960)

摘　　要：目的观察培美曲塞联合奈达铂治疗晚期乳腺癌的近期疗效及不良反应。方法 29例经蒽环类或紫杉类等药物化疗失败的晚期乳腺癌患者,给予培美曲塞联合奈达铂治疗,具体方案为:培美曲塞500 mg/m2静滴,第1天;奈达铂75 mg/m2静滴,第2天;3周1疗程,至少化疗2个疗程后评价疗效及不良反应。结果 29例患者均可评价疗效及不良反应。2例完全缓解(CR),10例部分缓解(PR),8例疾病稳定(SD),9例疾病进展(PD),总有效(CR+PR)12例(41.4%);疾病控制(CR+PR+SD)20例(69.0%)。主要不良反应为骨髓抑制、皮疹和胃肠道反应,经对症处理后均缓解。结论培美曲塞联合奈达铂治疗晚期乳腺癌疗效可靠,毒性反应轻,可耐受。Objective To observe short-term efficacy and adverse reactions of pemetrexed combined with nedaplatin in the treatment of advanced breast cancer. Methods 29 patients with advanced breast cancer after the treatment failure of anthracycline and taxane were enrolled in this study. Pemetrexed was given at a dose 500mg / m2ivgtt d1,with nedaplatin 75 mg / m2ivgtt d2,Three weeks was a cycle. The efficacy and adverse reactions were evaluated after at least two cycles of chemotherapy. Results Therapeutic efficacy and adverse reactions could be evaluated in all patients with 2 case of CR,10 cases of PR,8 cases of SD and 9 cases of PD.The response rate was 41. 4% and the disease control rate was 69. 0%. The main adverse reactions were myelosuppression,rash and gastrointestinal reaction,which were alleviated by symptomatic treatment. Conclusions Pemetrexed combined with lobaplatin for advanced breast cancer patients is reliable,low toxicity and well tolerated.

关 键 词：晚期乳腺癌 培美曲塞 奈达铂 疗效 不良反应 

分 类 号：R737.9[医药卫生—肿瘤]